Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children

被引:18
|
作者
Lasserson, Toby J. [1 ]
Ferrara, Giovanni [2 ,3 ]
Casali, Lucio
机构
[1] Cochrane Collaborat, Cochrane Editorial Unit, London W1G 0AN, England
[2] Univ Perugia, Dept Internal Med, Sect Resp Dis, Terni, Italy
[3] Karolinska Univ Hosp, Lung Allergi Kliniken, Stockholm, Sweden
关键词
Albuterol [administration & dosage; analogs & derivatives; Androstadienes [administration & dosage; Anti-Asthmatic Agents [administration & dosage; Asthma [drug therapy; Budesonide [administration & dosage; Drug Combinations; Ethanolamines [administration & dosage; Randomized Controlled Trials as Topic; Adult; Child; Humans; DRY POWDER INHALER; SALMETEROL/FLUTICASONE PROPIONATE; COST-EFFECTIVENESS; BUDESONIDE/FORMOTEROL MAINTENANCE; RELIEVER THERAPY; DOUBLE-BLIND; ALBUTEROL PMDI; MODERATE; ONSET; FORMOTEROL/BUDESONIDE;
D O I
10.1002/14651858.CD004106.pub4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Long-acting beta-agonists are a common second line treatment in people with asthma inadequately controlled with inhaled corticosteroids. Single device inhalers combine a long-acting beta-agonist with an inhaled steroid delivering both drugs as a maintenance treatment regimen. This updated review compares two fixed-dose options, fluticasone/salmeterol FP/SALand budesonide/formoterol, since this comparison represents a common therapeutic choice. Objectives To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma. Search methods We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of manufacturers' web sites and online trial registries. Search results are current to June 2011. Selection criteria We included randomised studies comparing fixed dose fluticasone/salmeterol and budesonide/formoterol in adults or children with a diagnosis of asthma. Treatment in the studies had to last for a minimum of 12 weeks. Data collection and analysis Two authors independently assessed studies for inclusion in the review. We combined continuous data outcomes with a mean difference (MD), and dichotomous data outcomes with an odds ratio (OR). We assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Main results Five studies met the review entry criteria (5537 adults). Study populations entered the studies having previously been treated with inhaled steroids and had moderate or mild airway obstruction (mean FEV1 predicted between 65% and 84% at baseline). Most of the studies assessed treatment over a period of six months. The studies were at a low risk of selection and performance/detection bias, although we could not determine whether missing data had an impact on the results. Availablility of outcome data was satisfactory. Primary outcomes The odds ratio for exacerbations requiring oral steroids was lower with fluticasone/salmeterol but did not reach statistical significance (OR 0.89, 95% confidence interval (CI) 0.74 to 1.07, four studies, N = 4949). With an assumed risk with budesonide/formoterol of 106/1000 participants requiring oral steroids, treatment with fluticasone/salmeterol would lead to between 25 fewer and seven more people per 1000 experiencing a course of oral steroids. Although the odds of hospital admission was higher with fluticasone/salmeterol, this did not reach statistical significance (OR 1.29, 95% CI 0.68 to 2.47, four studies, 4879 participants). With an assumed risk in the budesonide/formoterol of 7/1000, between two fewer and 10 more people per 1000 would be hospitalised on fluticasone/salmeterol. The odds of a serious adverse event related to asthma was higher with fluticasone/salmeterol but did not differ significantly between treatments (OR 1.47, 95% CI 0.75 to 2.86, three studies, 4054 participants). With an assumed risk in the budesonide/formoterol of 7/1000, between two fewer and 13 more people per 1000 would experience a serious adverse event on fluticasone/salmeterol. Secondary outcomes Lung function outcomes, symptoms, rescue medication, composite of exacerbations leading to either emergency department visit or hospital admission, withdrawals and adverse events did not differ statistically between treatments. Assessment of quality of life was limited to two studies, both of which gave results that did not reach statistical significance. One study reported one death out of 1000 participants on fluticasone/salmeterol and no deaths in a similar number of participants treated with budesonide/formoterol. No deaths were reported in the other studies. Authors' conclusions Statistical imprecision in the effect estimates for exacerbations and serious adverse events do not enable us to conclude that either therapy is superior. The uncertainty around the effect estimates justify further trials to provide more definitive conclusions; the overall quality of evidence based on GRADE recommendations for the three primary outcomes and withdrawals due to serious adverse events was moderate. We rated the quality of evidence for mortality to be low. Results for lung function outcomes showed that the drugs were sufficiently similar that further research is unlikely to change the effects. No trials were identified in the under-12s and research in this population is a high priority. Evaluation of quality of life is a priority for future research.
引用
收藏
页数:55
相关论文
共 50 条
  • [1] Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
    Lasserson, Toby J.
    Cates, Christopher J.
    Ferrara, Giovanni
    Casali, Lucio
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (03):
  • [2] Efficacy of Budesonide in Combination with Formoterol in Patients with Inadequately Controlled Asthma on Fluticasone in Combination with Salmeterol
    Kanemitsu, Yoshihiro
    Kita, Hideo
    Niimi, Akio
    Fuseya, Yoshinori
    Tanimura, Kazuya
    Katayama, Yuko
    Takahashi, Tamaki
    Hatachi, Yukimasa
    Nishihara, Yumi
    Sado, Toshikatsu
    [J]. ALLERGOLOGY INTERNATIONAL, 2012, 61 (04) : 625 - 627
  • [3] Budesonide/formoterol vs fluticasone/salmeterol combination therapies in asthma: An observational study
    Suissa, Samy
    Ernst, Pierre
    [J]. CHEST, 2007, 132 (04) : 478S - 479S
  • [4] Combination Therapy Salmeterol/Fluticasone Versus Doubling Dose of Fluticasone in Children With Asthma
    Vaessen-Verberne, Anna A. P. H.
    van den Berg, Norbert J.
    van Nierop, Jan C.
    Brackel, Hein J. L.
    Gerrits, Gerardus P. J. M.
    Hop, Wim C. J.
    Duiverman, Eric J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (10) : 1221 - 1227
  • [5] Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
    Vogelmeier, Claus
    Paggiaro, Pier Luigi
    Dorca, Jordi
    Sliwinski, Pawel
    Mallet, Marcel
    Kirsten, Anne-Marie
    Seoane, Beatriz
    Maria Segarra, Rosa
    Leselbaum, Anne
    Garcia Gil, Esther
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [6] Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone/Salmeterol Combination (FSC) Among Asthma Patients
    Williams, Setareh
    Tunceli, Ozgur
    Kern, David
    Pethick, Ned
    Elhefni, Hanaa
    Wessman, Catrin
    Zhou, Siting
    Trudo, Frank
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB236 - AB236
  • [7] Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis
    Jiang, Ping
    Zhao, Lanyu
    Yao, Zezhong
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1283 - 1289
  • [8] Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
    Kew, Kayleigh M.
    Karner, Charlotta
    Mindus, Stephanie M.
    Ferrara, Giovanni
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [9] Budesonide/salmeterol in fixed-dose combination for the treatment of asthma
    Popov, Todor A.
    De Niet, Sophie
    Vanderbist, Francis
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (02) : 113 - 125
  • [10] Evaluating the Differences in Characteristics of Asthma Patients Initiating Budesonide/Formoterol Combination (BFC) and Fluticasone/Salmeterol Combination (FSC)
    Trudo, Frank
    Tunceli, Ozgur
    Kern, David
    Pethick, Ned
    Elhefni, Hanaa
    Wessman, Catrin
    Zhou, Siting
    Williams, Setareh
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB108 - AB108